Suppr超能文献

血液捐献者生物库和 HLA 推测可作为用于治疗和研究目的的 HLA 纯合子细胞的资源。

Blood donor biobank and HLA imputation as a resource for HLA homozygous cells for therapeutic and research use.

机构信息

Blood Service Biobank, Finnish Red Cross Blood Service, Helsinki, Finland.

R&D, Finnish Red Cross Blood Service, Helsinki, Finland.

出版信息

Stem Cell Res Ther. 2022 Oct 9;13(1):502. doi: 10.1186/s13287-022-03182-7.

Abstract

BACKGROUND

Allogeneic therapeutic cells may be rejected if they express HLA alleles not found in the recipient. As finding cell donors with a full HLA match to a recipient requires vast donor pools, the use of HLA homozygous cells has been suggested as an alternative. HLA homozygous cells should be well tolerated by those who carry at least one copy of donor HLA alleles. HLA-A-B homozygotes could be valuable for HLA-matched thrombocyte products. We evaluated the feasibility of blood donor biobank and HLA imputation for the identification of potential cell donors homozygous for HLA alleles.

METHODS

We imputed HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 alleles from genotypes of 20,737 Finnish blood donors in the Blood Service Biobank. We confirmed homozygosity by sequencing HLA alleles in 30 samples and by examining 36,161 MHC-located polymorphic DNA markers.

RESULTS

Three hundred and seventeen individuals (1.5%), representing 41 different haplotypes, were found to be homozygous for HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1 alleles. Ten most frequent haplotypes homozygous for HLA-A to -DQB1 were HLA-compatible with 49.5%, and three most frequent homozygotes to 30.4% of the Finnish population. Ten most frequent HLA-A-B homozygotes were compatible with 75.3%, and three most frequent haplotypes to 42.6% of the Finnish population. HLA homozygotes had a low level of heterozygosity in MHC-located DNA markers, in particular in HLA haplotypes enriched in Finland.

CONCLUSIONS

The present study shows that HLA imputation in a blood donor biobank of reasonable size can be used to identify HLA homozygous blood donors suitable for cell therapy, HLA-typed thrombocytes and research. The homozygotes were HLA-compatible with a large fraction of the Finnish population. Regular blood donors reported to have positive attitude to research donation appear a good option for these purposes. Differences in population frequencies of HLA haplotypes emphasize the need for population-specific collections of HLA homozygous samples.

摘要

背景

如果异体治疗细胞表达受体中不存在的 HLA 等位基因,它们可能会被排斥。由于找到与受体 HLA 完全匹配的细胞供体需要大量的供体库,因此有人建议使用 HLA 纯合细胞作为替代方法。至少携带一份供体 HLA 等位基因的人应该能够很好地耐受 HLA 纯合细胞。HLA-A-B 纯合子可用于制造与 HLA 匹配的血小板产品。我们评估了血液库和 HLA 推测在鉴定潜在 HLA 等位基因纯合子细胞供体中的可行性。

方法

我们从 20737 名芬兰血液库献血者的基因型中推测出 HLA-A、-B、-C、-DRB1、-DQA1、-DQB1 和-DPB1 等位基因。通过对 30 个样本的 HLA 等位基因测序和对 36161 个 MHC 位置多态性 DNA 标记的检测,确认了纯合性。

结果

发现 317 人(1.5%)代表 41 种不同的单倍型,这些人 HLA-A、-B、-C、-DRB1、-DQA1 和-DQB1 等位基因纯合。HLA-A 至-DQB1 等位基因纯合的 10 个最常见单倍型与 49.5%的人群相容,3 个最常见的纯合子与 30.4%的芬兰人群相容。HLA-A-B 等位基因纯合的 10 个最常见单倍型与 75.3%的人群相容,3 个最常见的单倍型与 42.6%的芬兰人群相容。HLA 纯合子在 MHC 位置的 DNA 标记中杂合度较低,特别是在芬兰丰富的 HLA 单倍型中。

结论

本研究表明,在合理大小的血液库中进行 HLA 推测可以用于鉴定适合细胞治疗、HLA 型血小板和研究的 HLA 纯合子血液供体。这些纯合子与芬兰人群的很大一部分 HLA 相容。对研究捐赠有积极态度的常规献血者似乎是这些目的的不错选择。HLA 单倍型在人群中的频率差异强调了需要建立特定人群的 HLA 纯合子样本库。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb49/9549658/c5753a2e1601/13287_2022_3182_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验